JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells. JTX-1811 targets CCR8, a chemokine receptor enriched on TITR cells for depletion by an antibody-dependent cellular cytotoxicity mechanism. The program is on track to file an investigational new drug (IND) application in the first half of 2021.

Under the agreement, Gilead will make an $85 million upfront payment to, and a $35 million equity investment at a premium in, Jounce. Jounce may receive up to an additional $685 million in future clinical, regulatory, and commercial milestone payments. Jounce will also be eligible to receive royalties based on worldwide sales.

Jounce will lead development of JTX-1811 through IND clearance, at which point Gilead will have the sole right to develop JTX-1811.

The transaction is set to close in the second half of 2020.

Pfizer to manufacture remdesivir for Gilead
Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other...

Kite to manufacture CAR T-cell therapy in Europe
Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European...

Gilead licenses remdesivir to increase global access
Gilead Sciences has inked several agreements for the manufacture and distribution of remdesivir, which has been issued an emergency use authorization...

FDA issues EUA for remdesivir to treat severe COVID-19 cases
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir to be used...